measurement of qSOFA
OtherqSOFA will be measured at H0, H1 and H3
NCT Number: NCT02926664
The study will investigate the prognostic value of qSOFA (quick Sequential Organ Failure Assessment) kinetics between H0 and H1, and between H0 and H3 in patients with suspicion of Sepsis, i.e. an initial qSOFA of at least of 2.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Cliniques St Luc, Brussels, Belgium
qSOFA has been reported as a good tool for risk stratification in the ED for patients with infection.
However, it is not clear whether qSOFA remains stable during the ED stay, nor whether its kinetics can have prognostic added value.
Patients with a qSOFA of at least 2 in the ED, and suspicion of infection will be included.
After treatment is initiated and fluids challenge performed, we will collect qSOFA value at 1 hour and 3 hours.
Our hypothesis is that a decrease in qSOFA between H0 and H3 is associated with better outcome. We assume that 50% of patients will have a deltaqSOFA >0, with an overall mortality of 23% (according to previous cohort). Under the hypothesis of difference of at least 15% in mortality between the two groups (DeltaqSOFA > 0 and Delta qSOFA<=0), with a power of 90% and an alpha of 0.05, we need to recruit 322 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
qSOFA will be measured at H0, H1 and H3
Time frame: 60 days
Time frame: 60 days
Time frame: 60 days
Societe Française de Medecine d'urgence
Other
Prognostic Value of Quick Sequential Organ Failure Assessment Kinetics After Fluids Challenge in the Emergency Department
Acronym: DELTASCREEN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06541600
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsNCT06080282
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsNCT07025096
Acute Respiratory Distress Syndrome (ARDS), Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06876168
Acute Respiratory Failure, Infections
Lexington, Kentucky, United States
View Trial Details